12 results about "Tonicity" patented technology

An aqueous solution composition having a pH in the range of 4.0 to 8.5, comprising: an antibody construct comprising an Fc domain; optionally, one or more buffering agents which are a substance having at least one ionizable group, have a pKa in the range of 3.0 to 9.5, and have a pKa within 2 pH units of the pH of the composition; optionally, one or more neutral amino acids; and an uncharged tension regulator; wherein the total concentration of the buffer in the composition is 0-5 mM; and wherein the composition has a total ionic strength of less than 20 mM, excluding the contribution of engineered protein constructs.

The present invention relates to the use of a liquid aqueous composition comprising a tonicity agent, a buffering agent, a non-ionic surfactant and a polysaccharide, and having a pH of from 5 to 7, for solubilization and stabilization of an antibody-drug conjugate during a period T equal or greater than 3 months at a temperature Θ of from 2° C. to 8° C.

An aqueous solution composition of pH in the range 4.0-8.5 comprising:an antibody construct comprising an Fc domain;optionally one or more buffers being substances having at least one ionisable group with a pKa in the range 3.0 to 9.5 and which pKa is within 2 pH units of the pH of the composition;optionally one or more neutral amino acids; andan uncharged tonicity modifier;wherein the buffers are present in the composition at a total concentration of 0-5 mM; andwherein the total ionic strength of the composition excluding the contribution of the engineered protein construct is less than 20 mM.

An aqueous formulation includes a PEDF-derived short peptide (PDSP) having the sequence of one of SEQ ID NO: 1, 2, 3, 5, 6, 8, or 9; histidine having a concentration of 1 mM – 100 mM; and an antioxidant and optionally a non-ionic tonicity agent. The pH value is around 5–9. The antioxidant is nicotinamide, which is at a concentration of 50 mM – 1000 mM. The non-ionic tonicity agent is sorbitol, which is at a concentration of 0 mM – 500 mM. A concentration of the PDSP is 0.01% - 1% w / v.

The present invention provides a formulation that includes a therapeutically effective amount of phenylephrine or a pharmaceutically acceptable salt thereof, and a method for preparing the formulation. In some embodiments, the formulation includes a tonicity agent, a citrate buffer, water, and has an initial pH of from 5.6 to 6.0. In other embodiments, the formulation includes a tonicity agent, a citrate buffer, an antioxidant, water, and has an initial pH of from 3.6 to 4.8. The formulation of the invention is sterile, stable, ready-to-administer and packaged into a polymeric syringe.

A test method determines at least one status parameter of an individual undergoing peritoneal dialysis. The status parameter(s) may include a transport property of the peritoneum, a tonicity, or a residual volume. The test method includes receiving first data indicative of a flow rate as a function of time of a treatment fluid into and out of a peritoneal cavity during a test procedure, and second data comprising measured data samples representing a concentration of one or more solutes in the treatment fluid at time points during the test procedure. The test method also includes computing, based on the first data and by use of a transport model for a peritoneal membrane, estimated data samples representing the concentration of the one or more solutes in the treatment fluid at the time points and determining the status parameter(s) as a function of the measured data samples and the estimated data samples.

A triamcinolone acetonide pharmaceutical composition and a preparation method therefor. The pharmaceutical composition contains the following ingredients: (i) a triamcinolone acetonide active ingredient, (ii) hyaluronic acid or a salt thereof. (iii) a buffering agent; and (iv) a tonicity adjustment agent. The pharmaceutical composition has a suitable viscosity, osmotic pressure and particle size range and is easily injected, especially administrated by means of a suprachoroidal space injection.

A nuclear magnetic resonance (NMR) system measures an effective osmolarity or tonicity and characterizes the effective osmolarity or tonicity's effect on water exchange in a specimen. The NMR system includes a magnetic resonance (MR) device, which has: a magnetic field generator; a magnetic field gradient generator; a radio frequency (RF) transmitter; and a RF receiver. The NMR system also includes a processing system coupled to the MR device. The processing system is configured to: receive sample NMR data from the MR device, the sample NMR data corresponding to the specimen; estimate an exchange rate from the NMR data, the exchange rate corresponding to the water exchange through a semipermeable membrane of the specimen; and estimate the effective osmolarity or tonicity based on the estimated exchange rate.

The present invention relates to Human Immunodeficiency Virus (HIV) prevention and treatment. In particular, the invention relates to a pharmaceutical composition comprising: cabotegravir, a wetting agent; a stabilizer, and a tonicity adjuster, wherein cabotegravir is present in the form of particles having a mass median diameter (X50) of between (and including) 2.5 μm and 10 μm.

The present invention relates to a liquid formulation comprising (i) a botulinum toxin, (ii) human serum albumin (HSA), (iii) hyaluronic acid, (iv) a sugar alcohol, and optionally (v) a tonicity agent and / or (vi) a buffer. In a preferred embodiment, the HSA has been treated with a chelating agent. Furthermore, the present invention relates to the use of said liquid formulation in the treatment of therapeutic and cosmetic indications.

The invention provides a stable, pharmaceutical formulation comprising epinephrine or a pharmaceutically acceptable salt thereof. The formulation includes an organic acid, a tonicity agent, and water, has a pH of about 3.0 to about 3.6, and is substantially free of a conjugate base of the organic acid.

Disclosed herein are pharmaceutical compositions comprising (a) a fluorescein labeled nerve targeting peptide of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate or isotope thereof: (I) (b) an additive comprising a pH regulator, a buffer, a filler, a tonicity regulator, a preservative, or any combination thereof; and (c) an aqueous vehicle wherein the pH of the composition is from about 7 to about 9 and the concentration of the peptide in the aqueous composition is from about 25 mg / mL to about 200 mg / mL based on the total volume of the aqueous composition. Also disclosed are methods for making and using the pharmaceutical compositions described herein.